Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06013410
Other study ID # 2023-0381
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 25, 2023
Est. completion date May 15, 2026

Study information

Verified date June 2023
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact WEI WEI
Phone 15267175186
Email wwze@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to explore the pathophysiological effects of the persistently colonized microbiome in irritable bowel syndrome (IBS) patients. The main questions it aims to answer are: Question 1: the microbiome difference of the biofilm between IBS and healthy patients. Question 2: the metabolic product patterns between IBS and healthy patients. Participants will need to take a colonoscopy examination, two gut mucosal biopsy samples will be collected during the examination. Researchers will compare the IBS and healthy control groups to see if there was the disease-specific pattern in the microbiome and metabolic product of the biofilm.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 15, 2026
Est. primary completion date May 10, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - IBS patients with IV type; no abdominal surgery; Exclusion Criteria: - age <18 y; - major disease; - alcoholic addicted; - antibiotic use in past 3 months; - severe gastrointestinal disease - severe cardiac disease; - pregnant; - ICU in past 1 year; - vegeterian; - immune disease (SLE etc.) - mental disease;

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
colonoscopy
colonoscopy

Locations

Country Name City State
China 2ndAffiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University Jinhua Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary mirobiome difference of the fecal between IBS and health controls 16S rDNA sequencing will be applied in fecal samples all the above participants Fecal samples will be collected immediately before the colonoscopy (T1) and 7 days after the colonoscopy test (T2)
Primary mirobiome difference of the fecal between IBS and health controls 16S rDNA sequencing will be applied in fecal samples all the above participants Fecal samples will be collected 7 days after the colonoscopy test (T2)
Primary Metabolic changes between IBS and Healthy controls mucosal biopsy will be collected during the colonoscopy in each patients 1 day biopsy will be collected during the colonoscopy test
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A